Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomized, double-blind, placebo-controlled, crossover study.

Authors: Haines C, Chung T, Chang A, Masarei J, Tomlinson B, Wong E.

Publication Year: 1996

Citation: Arch Intern Med 1996;156(8):866-72.

In a randomized, double-blind, placebo-controlled, crossover study, 91 surgically postmenopausal women received either 6 months of 2mg daily oral estradiol followed by 6 months of placebo or the opposite regimen. During treatment phase, Group One showed decreased Lipoprotein (a) concentration (10.78 to 6.44 mg/dL) and LDL-C with increase in HDL-C and TG while Group Two showed a less pronounced decrease (12.74 to 10.75). 53 women continued oral estrogen therapy for an additional 12 months. Lipoprotein (a) levels were essentially unchanged from previous measures at the end of the treatment phase after 12 months of additional therapy. Authors suggested that reduced Lipoprotein (a) levels with extended oral estrogen therapy support a cardioprotective effect of HRT in postmenopausal women.